Bagoly, Z.; Baráth, B.; Orbán-Kálmándi, R.; Szegedi, I.; Bogáti, R.; Sarkady, F.; Csiba, L.; Katona, É.
Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients. Biomolecules 2021, 11, 347.
https://doi.org/10.3390/biom11030347
AMA Style
Bagoly Z, Baráth B, Orbán-Kálmándi R, Szegedi I, Bogáti R, Sarkady F, Csiba L, Katona É.
Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients. Biomolecules. 2021; 11(3):347.
https://doi.org/10.3390/biom11030347
Chicago/Turabian Style
Bagoly, Zsuzsa, Barbara Baráth, Rita Orbán-Kálmándi, István Szegedi, Réka Bogáti, Ferenc Sarkady, László Csiba, and Éva Katona.
2021. "Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients" Biomolecules 11, no. 3: 347.
https://doi.org/10.3390/biom11030347
APA Style
Bagoly, Z., Baráth, B., Orbán-Kálmándi, R., Szegedi, I., Bogáti, R., Sarkady, F., Csiba, L., & Katona, É.
(2021). Incorporation of α2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients. Biomolecules, 11(3), 347.
https://doi.org/10.3390/biom11030347